News Search Results
Feb 10, 2026, 20:36 ET IINO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Inovio Pharmaceuticals, Inc.
purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Robbins LLP
Feb 10, 2026, 18:15 ET Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development
dose of the same drugAbout Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Feb 10, 2026, 18:02 ET INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.Details of the case: Inovio describes itself as a "biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: THE ROSEN LAW FIRM, P. A.
Feb 10, 2026, 16:05 ET Nektar Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy, today announced that it has commenced an underwritten
More news about: Nektar Therapeutics
Feb 10, 2026, 16:05 ET Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Feb 10, 2026, 13:22 ET ISPE Announces its 2026 ISPE Aseptic Conference Keynote Speakers
for collaboration, the 2026 conference in Washington, D.C. will be the year's most influential forum for professionals across the pharmaceutical, biotechnology, and advanced therapy sectors. We've designed this program to tackle the industry's most urgent challenges and emerging opportunities head on."ISPE
More news about: ISPE
Feb 10, 2026, 11:58 ET Regenerative Medicine Market to Reach $531.7 billion, Globally, by 2033 at 32.4% CAGR: Allied Market Research
Asia-Pacific is projected to grow at a faster pace, driven by expanding healthcare access, rising clinical trial activity, and government support for biotechnology development.Want to Explore More, Connect to our Analyst –
More news about: Allied Market Research
Feb 10, 2026, 11:17 ET Made Scientific and Streamline Bio Launch Exclusive Early Adopter Program to Advance AI-Driven Robotic Automation for Cell Therapy Manufacturing
spirit of a specialist CDMO with the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors. For more information, visit
More news about: Made Scientific, Inc.
Feb 10, 2026, 10:00 ET FYR Bio Appoints Barbara K. Zehentner, MBA, PhD, HCLD (ABB), as Chief Operating Officer
FYR Bio ("FYR"), a biotechnology company leveraging extracellular vesicles (EVs) to deliver AI-enabled multiomic insights from a peripheral blood sample, today announced the appointment
More news about: FYR Bio
Feb 10, 2026, 09:30 ET Greenberg Traurig Adds Employee Benefits Shareholder Lisa H. Barton in Boston Office
growth, and change."Barton's hiring also represents the latest expansion for Greenberg Traurig in Boston, a global hub for the life sciences, biotechnology, pharmaceutical, and health care industries. Since opening an office there in 1999, the team has grown to more than 100 lawyers across a wide range
More news about: Greenberg Traurig, LLP
Feb 10, 2026, 09:00 ET SickScience Launches at Ulta Beauty, Bringing Clinically-Driven Biotech Beauty to a National Retail Stage
Bridging clinical science and skincare, SickScience applies biohacking and biotechnology innovation to deliver cellular regeneration through its proprietary NX35™ Exosome Technology — a 100% vegan, plant-based system that mimics the
More news about: SickScience
Feb 10, 2026, 08:00 ET AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases
CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative
More news about: Insilico Medicine
Feb 10, 2026, 07:00 ET New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
SAN FRANCISCO, Feb. 10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced positive results from the 36-week blinded maintenance period of the
More news about: Nektar Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options
BARCELONA, Spain, Feb. 10, 2026 /PRNewswire/ -- Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, today announced the initiation of a Phase I/IIa clinical trial of GYA01
More news about: Gyala Therapeutics
Feb 10, 2026, 06:00 ET Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options
BARCELONA, Spain, Feb. 10, 2026 /PRNewswire/ -- Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, today announced the initiation of a Phase I/IIa clinical trial of GYA01
More news about: Gyala Therapeutics
Feb 09, 2026, 21:00 ET MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease
TAINAN, Feb. 10, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive Phase 1 results for TML-6, its investigational oral therapy for Alzheimer's
More news about: Merry Life Biomedical Company, Ltd.
Feb 09, 2026, 21:00 ET MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Disease
TAINAN, Feb. 9, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive Phase 1 results for TML-6, its investigational oral therapy for Alzheimer's
More news about: Merry Life Biomedical Company, Ltd.
Feb 09, 2026, 17:31 ET Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight
affecting immunocompromised populations, together contributing around 50% of the total burden.Several leading pharmaceutical and biotechnology companies including Glaxosmithkline, SCYNEXIS, Basilea Pharmaceutica, Shionogi, F2G, Pulmocide, Mycovia Pharmaceuticals, Matinas BioPharma, Biosergen,
More news about: DelveInsight Business Research, LLP
Feb 09, 2026, 16:15 ET Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline
More news about: Nektar Therapeutics
Feb 09, 2026, 16:05 ET REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
which has been shown to correlate with neurocognitive manifestations of the disorder.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Feb 09, 2026, 14:18 ET DOE Partners with RTI International to Administer Newly Launched Genesis Mission Consortium Via TechWerx
energy innovation, discovery science and national security by applying its capabilities to major national challenges—from advanced manufacturing and biotechnology to materials science, nuclear energy, quantum information science and semiconductors."Our role is to provide structured partnerships between
More news about: RTI International
Feb 09, 2026, 09:47 ET Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
has acquired all outstanding shares of Arthrosi's common stock and common stock equivalents.Arthrosi Therapeutics is a private late-stage biotechnology company focused on developing a next-generation treatment for gout. The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882),
More news about: Swedish Orphan Biovitrum AB
Feb 09, 2026, 09:20 ET NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has
More news about: NeuroSense
Feb 09, 2026, 09:15 ET Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data
BioworksLunai Bioworks (NASDAQ: LNAI) is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biotechnology. Leveraging advanced machine learning and proprietary phenotypic and neurotoxicity datasets, Lunai is redefining how artificial intelligence can
More news about: Lunai Bioworks Inc.
Feb 09, 2026, 09:07 ET Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol
More news about: Innocan Pharma Corporation